A novel thioredoxin reductase inhibitor inhibits cell growth and induces apoptosis in HL-60 and K562 cells.
- Author:
Zuo-Fu PENG
1
;
Lin-Xiang LAN
;
Fang ZHAO
;
Jing LI
;
Qiang TAN
;
Han-Wei YIN
;
Hui-Hui ZENG
Author Information
- Publication Type:Journal Article
- MeSH: Apoptosis; drug effects; Bridged Bicyclo Compounds, Heterocyclic; pharmacology; Cell Proliferation; drug effects; Enzyme Inhibitors; pharmacology; HL-60 Cells; Humans; K562 Cells; Organoselenium Compounds; pharmacology; Proto-Oncogene Proteins c-bcl-2; physiology; Thioredoxin-Disulfide Reductase; antagonists & inhibitors; bcl-2-Associated X Protein; physiology
- From: Journal of Zhejiang University. Science. B 2008;9(1):16-21
- CountryChina
- Language:English
- Abstract: Human thioredoxin reductase (TrxR) system is associated with cancer cell growth and anti-apoptosis process. Effects of 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane (BBSKE), a novel TrxR inhibitor, were investigated on human leukemia cell lines HL-60 and K562. BBSKE treatment induced cell growth inhibition and apoptosis in both cell lines. Apoptosis induced by BBSKE is through Bcl-2/Bax and caspase-3 pathways. Ehrlich's ascites carcinoma-bearing mice were used to investigate the anti-tumor effect of BBSKE in vivo. Tumor-bearing mice treated with BBSKE showed an increase of life span with a comparable effect to cyclophosphamide (CTX). These results suggest a potential usage of BBSKE as a therapeutic agent against non-solid tumors.
